Results 211 to 220 of about 89,766 (303)

Oral Bioavailability of Monoclonal Antibody. [PDF]

Pharmaceutics
Verma A, Wu S, Shah DK.
europepmc   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Understanding Biologics in CRSwNP: Related Events and Insights. [PDF]

Curr Allergy Asthma Rep
Izquierdo-Domínguez A, Al-Salloom Z, Viñas M, Mullol J, Alobid I.   +4 more
europepmc   +1 more source

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior, Volume 16, Issue 5, May 2026.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
wiley   +1 more source

Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model. [PDF]

J Virol
Yu W, He X, Zhao J, Dou Y, Hu T, Chen X, Ma X, Wang X, Hu S, Hu J, Liu X, Hu Z.   +11 more
europepmc   +1 more source

Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT The efficacy of PD‐1 inhibitor pucotenlimab (HX008) in solid tumors exhibits heterogeneity. This study integrated data from 6 clinical trials (covering gastric/gastroesophageal junction cancer, triple‐negative breast cancer, melanoma, and dMMR/MSI‐H solid tumors) using Bayesian meta‐analysis, machine learning (optimal XGBoost AUC = 0.86), and ...
Yingge He, Changqing Gao, Shiyan Zhang, Yonghui Hao, Shuning He, Ke Peng, Liqi Li   +6 more
wiley   +1 more source

Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab. [PDF]

Diabetes Care
Mathieu C, Mathieu C, Sims EK, Chatenoud L, James EA, Atkinson MA, Herold KC.   +6 more
europepmc   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Advances in immunotherapy and targeted therapy for nasopharyngeal carcinoma: Current progress and combined approaches (Review). [PDF]

Oncol Rep
Yang Z, Liu H, Chen M, Zhang L, Gong M, Yu R.   +5 more
europepmc   +1 more source

Primary Cardiac Lymphoma: A Diagnostically Challenging Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT This case highlights the diagnostic difficulties of PCL, including non‐specific symptoms, imaging mimics, and the critical role of histopathological confirmation despite technical and clinical challenges. Early multidisciplinary evaluation is essential to improve outcomes in this aggressive disease.
Yucheng Huang, Minxi Lao, Min Ye, Yang Yang, Meilin Ding, Jin Li, Lei Su   +6 more
wiley   +1 more source